Bringing all the omics together -- Dr. Szilard Voros, CEO of Global Genomics Group (G3), shares how he and his team of researchers embarked on an ambitious journey to transform drug discovery using big data. With 48 participating clinical sites, three continents, nine countries, and nearly 8,000 patients, the study is the largest clinical trial to date that has used a multiomics approach to look at trends in disease states.